Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to elucidate whether the individualized medicine based on NAT2 gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug therapy for the pulmonary tuberculosis with isoniazid.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Osaka University
• Treatments: Isoniazid

Criteria

Inclusion Criteria:

• Newly diagnosed pulmonary tuberculosis patients

• Informed consent including pharmacogenomic analysis

Exclusion Criteria:

• Abnormal liver and kidney function test before treatment

• Long-term use of steroids and/or immunodepressants

• Inadequate clinical conditions